Autolus Therapeutics (AUTL) News Today $1.65 +0.08 (+5.10%) Closing price 04:00 PM EasternExtended Trading$1.64 -0.01 (-0.61%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Comparing Autolus Therapeutics (NASDAQ:AUTL) & ImmunityBio (NASDAQ:IBRX)May 27 at 1:49 AM | americanbankingnews.comCetera Investment Advisers Increases Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Cetera Investment Advisers grew its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 169.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 356,222 shares of the company's stock after buying anMay 26 at 3:33 AM | marketbeat.comAutolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute ...May 25 at 5:25 PM | morningstar.comAutolus Therapeutics Receives Positive CHMP Opinion for Obecabtagene Autoleucel in Treating Adult Patients with Relapsed or Refractory B-ALLMay 25 at 5:25 PM | nasdaq.com247,089 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. purchased a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 247,089 shares of the company's stock, valued at approMay 25 at 4:04 AM | marketbeat.comAutolus Therapeutics gets EU endorsement for leukemia treatmentMay 23, 2025 | msn.comAutolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment BrightensMay 23, 2025 | msn.comAutolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)May 23, 2025 | globenewswire.comAutolus Therapeutics plc (AUTL): Analysts See 697% Upside PotentialMay 20, 2025 | insidermonkey.comTFG Asset Management GP Ltd Buys 250,000 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)TFG Asset Management GP Ltd increased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,250,000 shares of theMay 20, 2025 | marketbeat.comAutolus Therapeutics Announces Upcoming Presentations at the European Hematology Association Congress 2025May 17, 2025 | nasdaq.comAutolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) CongressMay 14, 2025 | globenewswire.comAutolus Therapeutics (NASDAQ:AUTL) Issues Quarterly Earnings ResultsAutolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02).May 12, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Receives Consensus Rating of "Buy" from AnalystsAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) has earned an average recommendation of "Buy" from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target amonMay 12, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (VCEL), Autolus Therapeutics (AUTL) and Pacira Pharmaceuticals (PCRX)May 11, 2025 | theglobeandmail.comAutolus Therapeutics plc (AUTL) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comAxa S.A. Makes New Investment in Autolus Therapeutics plc (NASDAQ:AUTL)Axa S.A. purchased a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,824,685 shares of the company's stock, valued aMay 10, 2025 | marketbeat.comAutolus Therapeutics PLC (AUTL) Q1 2025 Earnings Call Highlights: Strong US Launch and ...May 9, 2025 | finance.yahoo.comDeep Track Capital LP Cuts Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Deep Track Capital LP decreased its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 6.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,218,903 shares of the company's stock afterMay 9, 2025 | marketbeat.comAutolus Therapeutics Reports First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comPrice T Rowe Associates Inc. MD Sells 902,261 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Price T Rowe Associates Inc. MD lowered its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,939,241 shares of the company's stock after selling 902,261 sharesMay 6, 2025 | marketbeat.comAutolus Therapeutics (AUTL) Projected to Post Quarterly Earnings on ThursdayAutolus Therapeutics (NASDAQ:AUTL) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-autolus-therapeutics-plc-stock/)May 3, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Stake Boosted by Renaissance Technologies LLCRenaissance Technologies LLC increased its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 146.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 618,942 sharApril 30, 2025 | marketbeat.comLegal & General Group Plc Buys 237,224 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Legal & General Group Plc grew its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 392.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 297,736 shares of the company's stock after buying an additional 237,22April 30, 2025 | marketbeat.comWalleye Capital LLC Trims Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)Walleye Capital LLC trimmed its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 92.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 75,940 shares of the company's stock after selling 986,453 shares during the period. Walleye Capital LLCApril 29, 2025 | marketbeat.comAutolus Therapeutics’ obecabtagene autoleucel conditionally approved by MHRAApril 27, 2025 | markets.businessinsider.comQ1 Earnings Estimate for AUTL Issued By William BlairAutolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Analysts at William Blair issued their Q1 2026 EPS estimates for shares of Autolus Therapeutics in a report issued on Wednesday, April 23rd. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.27) per shareApril 27, 2025 | marketbeat.comAutolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRAApril 26, 2025 | finance.yahoo.comUK approves Autolus leukemia therapy with conditionsApril 26, 2025 | investing.comAutolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)April 25, 2025 | globenewswire.comJPMorgan Chase & Co. Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)JPMorgan Chase & Co. lowered its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 16.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,071,533 shares of the company's stock after selling 213,175 shApril 25, 2025 | marketbeat.comEversept Partners LP Sells 307,663 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Eversept Partners LP decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 75.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,895 shares of the company's stock after selling 307,663April 24, 2025 | marketbeat.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | finance.yahoo.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | globenewswire.comAvoro Capital Advisors LLC Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Avoro Capital Advisors LLC cut its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 19.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,910,642 shares of the company's stock after selling 2,435,0April 23, 2025 | marketbeat.comAutolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025April 22, 2025 | globenewswire.comAutolus Therapeutics (NASDAQ:AUTL) Stock, Option ChainApril 18, 2025 | benzinga.comAutolus Therapeutics plc (NASDAQ:AUTL) Receives Average Recommendation of "Buy" from BrokeragesAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) has been assigned a consensus rating of "Buy" from the six analysts that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price amongApril 17, 2025 | marketbeat.comAutolus Therapeutics' (AUTL) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday.April 12, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Wellington Management Group LLPWellington Management Group LLP increased its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 4.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,345,680 shares of the company's stock after acquApril 7, 2025 | marketbeat.comTruist Financial Lowers Autolus Therapeutics (NASDAQ:AUTL) Price Target to $10.00Truist Financial lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday.April 2, 2025 | marketbeat.comAutolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comAutolus Therapeutics price target lowered to $10 from $11 at TruistApril 1, 2025 | markets.businessinsider.comAutolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025April 1, 2025 | globenewswire.comBIT Capital GmbH Buys 379,050 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)BIT Capital GmbH increased its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 147.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 636,979 shares of the company's stock after acquiring an additional 37March 28, 2025 | marketbeat.com191,429 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Bought by EntryPoint Capital LLCEntryPoint Capital LLC purchased a new stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 191,429 shares of the company's stock, valued at approximately $450,000.March 27, 2025 | marketbeat.comEquities Analysts Offer Predictions for AUTL FY2028 EarningsAutolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Investment analysts at William Blair issued their FY2028 earnings per share estimates for shares of Autolus Therapeutics in a research note issued to investors on Thursday, March 20th. William Blair analyst M. Phipps forecasts that the companMarch 24, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Given Consensus Recommendation of "Buy" by BrokeragesShares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year price oMarch 22, 2025 | marketbeat.comWells Fargo & Company Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock PriceWells Fargo & Company lowered their target price on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.com Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Media Mentions By Week AUTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUTL News Sentiment▼0.920.93▲Average Medical News Sentiment AUTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUTL Articles This Week▼93▲AUTL Articles Average Week Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bausch Health Companies News Today Biohaven News Today Schrödinger News Today Immunocore News Today Indivior News Today Edgewise Therapeutics News Today Janux Therapeutics News Today ARS Pharmaceuticals News Today Qilian International Holding Group News Today Structure Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUTL) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts